Outsourcing channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP NOW
Subscribe to Endpoints News

Ver­i­ly scoops up a fel­low soft­ware mak­er as Amy Aber­nethy scales its clin­i­cal tri­als plat­form

Amy Abernethy now has a whole new set of tools to tap into as she scales up the clinical trial management platform at Verily.

The life sciences outfit — now officially a subsidiary of Alphabet on equal footing with Google — has acquired SignalPath for an undisclosed amount, giving it access to a system of digital solutions that make it easier to run clinical trials, and promise to simultaneously boost quality and efficiency.

Alan Hirzel, Abcam

Ab­cam brings a long­time col­lab­o­ra­tor in house as part of $340M buy­out pact

BioVision has supplied Abcam with research tools since 1999, and now the two are making it official as part of a merger unveiled Monday.

Abcam will buyout BioVision as part of a $340 million acquisition deal to bring aboard the supplier’s biochemical and cell-based assays for biological research, as well as recombinant proteins, antibodies and enzymes.

The deal will give Abcam control of BioVision’s portfolio and allow for both the expansion of research existing areas of focus such as oncology, neuroscience and epigenetics and preparation to expand into new products. As a part of the deal, Abcam will develop and supply products and services to NKY, the previous owner of BioVision and receive support for ongoing development and commercialization of in vitro diagnostic products.

Prahlad Singh, PerkinElmer CEO

Shelling out $5B+, PerkinElmer pays the big bucks for an­ti­body and reagent play­er

PerkinElmer has been busy on the acquisition front throughout the Covid-19 pandemic, and on Monday, the Massachusetts-based diagnostics and life sciences company added the biggest feather to its cap.

PerkinElmer will acquire antibody and reagents provider BioLegend for nearly $5.25 billion, the entities announced Monday morning. The deal is PerkinElmer’s third acquisition since November 2020 as it kicked development of Covid-19 testing into high gear, as well as the company’s biggest buyout ever.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.

Re­ci­pharm to con­struct new In­di­an fill-fin­ish fa­cil­i­ty as part of ex­ist­ing re­la­tion­ship with Nichep­harm found­ing fam­i­ly'

India is getting a manufacturing boost that will add the capacity to produce another 1 billion injectables.

Recipharm announced the construction of a new fill-finish facility in Uttarakhand, near Dehradun, in collaboration with the Sobti family. The development is the latest move in a partnership with the family, which began in 2019 after Recipharm invested in Nichepharm.

The site will up Recipharm’s sterile fill-finish service to complement already existing locations in France, Germany and Italy. The project’s next step is to gain authorization from European regulators.

Catal­ent keeps adding on at key Ital­ian plant, this time with a pair of new biore­ac­tors and 100 jobs

For the second time in less than six months, Catalent will upgrade its sleek new facility in Anagni, Italy, this time to add biologics drug substance manufacturing capabilities to support an increase in demand.

Two new 2,000 liter single-use bioreactors with new manufacturing suites will support early-phase clinical development and late-stage commercial transfers, the company said in a press release, as well as space for another six bioreactors to be added in the future. The project is expected to add 100 new employees, and it should be operational in April 2023.

Catal­ent lands 2 new part­ner­ships, in­clud­ing for glioblas­toma drug; US drops $153M in­to pan­dem­ic pre­pared­ness

It’s been a quiet few weeks for one of the busiest CDMOs out there, but Catalent broke its lull with the announcement of two partnerships this week.

Curtana Pharmaceuticals, an Austin, TX-based preclinical company, announced a partnership with the manufacturer Thursday to make CT-179, its drug therapy for glioblastoma, medulloblastoma and other brain cancers.

CT-179 is a selective small molecule inhibitor of LIG2, a transcription factor essential to early brain development but often not expressed in adult brain cells. The development will take place at Catalent’s San Diego facility.

Jaime Shamonki, Generate CMO

Al­ready sit­ting on a ma­jor stem cell bank, Gen­er­ate looks to grow its re­gen­er­a­tive med­i­cines busi­ness

Generate Life Sciences is the largest private newborn stem cell biorepository, and with the announcement of its own in-house manufacturing facility, the company is looking to grow its regenerative medicine pipeline.

Generate has established a facility in La Jolla, CA, to provide end-to-end manufacturing for newborn stem cell biologics. The site will allow Generate to evolve as it adds a personalized therapeutics developer to its current business model. The new site has been designed to harness mesenchymal stem cells from the tissue of the umbilical cord.

Fabian Gerlinghaus (Cellares)

A cou­ple months af­ter land­ing $100 mil­lion in fund­ing, Cel­lares grabs part­ner for its Cell Shut­tle

The team at Cellares hopes that its Cell Shuttle is the future of end-to-end cell therapy manufacturing. On Wednesday, the company announced that one more company has signed up to work alongside it.

Poseida has signed on to provide therapies for the Cell Shuttle, a portable factory Cellares hopes will disrupt the expensive and logistically complicated cell therapy manufacturing process. The company is the third to ink a deal with Cellares, which is based out of South San Francisco, CA. Cellares has already has been collaborating with PACT Pharma and the Fred Hutchinson Cancer Research Center.

Marc Funk, Recipharm

Mo­roc­can gov­ern­ment drops $500M in­to new Re­ci­pharm fill-fin­ish plant in big boost for African man­u­fac­tur­ing

Recipharm has inked a deal with the Moroccan government to build a new fill-finish factory over the next five years to up vaccine and therapeutic capacity and capability, the company announced Tuesday.

The Moroccan government will invest $500 million in the build, which will be primary dedicated to African vaccine manufacture.

The factory will be operational by 2023, if all goes according to plan, and will mirror the company’s current fill-finish site in Monts, France; except at 107,000 square feet, it will be operating on a much larger scale. Recipharm will not be on the hook for any of the money going into the plant, just its operations, a spokesperson for the company confirmed in an email to Endpoints News on Thursday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.

FDA hands a warn­ing let­ter to a Lupin sub­sidiary af­ter fail­ing to main­tain clean­li­ness once again

From India to NJ, the core of the FDA’s instructions to Lupin subsidiary Novel Laboratories were the same: establish proper cleaning and process validation guidelines at your manufacturing sites. And after failing to do so for the third time in four years, the company has received a warning letter.

Drug residue on tablet presses and a failure to validate the manufacturing process after equipment changes were just two of the issues raised by the FDA after an inspection of a Novel Laboratories plant that led to the June 11 letter.